DOCN DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages DigitalOcean Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 13 Deadline in Securities Class Action – DOCN

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DigitalOcean Holdings, Inc. (NYSE: DOCN) between February 16, 2023 and August 25, 2023, both dates inclusive (the “Class Period”), of the important November 13, 2023 lead plaintiff deadline.

SO WHAT: If you purchased DigitalOcean securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the DigitalOcean class action, go to https://rosenlegal.com/submit-form/?case_id=18119 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) defendants lacked the skills and experience to assess complicated tax matters and therefore did not design or maintain effective controls over DigitalOcean’s accounting for income taxes; and (2) as a result of the foregoing, defendants’ financial statements during the Class Period were inaccurate and materially misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the DigitalOcean class action, go to https://rosenlegal.com/submit-form/?case_id=18119 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8976627

ROSEN, A LEADING LAW FIRM, Encourages Lumen Technologies, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 14 Deadline in Securities Class Action – LUMN

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lumen Technologies, Inc. (NYSE: LUMN) between March 11, 2019 and July 14, 2023, both dates inclusive (the “Class Period”), of the important November 14, 2023 lead plaintiff deadline.

SO WHAT: If you purchased Lumen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lumen class action, go to   https://rosenlegal.com/submit-form/?case_id=17736 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 14, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Lumen owned and/or still owns thousands of miles of cables wrapped in lead, a known neurotoxin, within the United States of America; (2) the foregoing has harmed and posed the risk of further harming the environment, exposed Lumen employees, and the general public, thereby posing a significant public health risk and environmental pollution risk; (3) Lumen was on notice about the damage and risks presented by these lead-covered cables but did not disclose them as a potential threat to everyday people and communities, as well as failed to provide adequate lead training to employees; (4) all the foregoing subjected Lumen to a heightened risk of governmental and regulatory oversight and enforcement action, as well as legal and reputational harm; and (5) as a result, Lumen’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lumen class action, go to https://rosenlegal.com/submit-form/?case_id=17736 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8976647

Nigerian Lawyer Zannah Bukar Mustapha Receives Prestigious Global Citizen Award

Nigerian Lawyer Zannah Bukar Mustapha Receives Prestigious Global Citizen Award

Internationally recognized humanitarian, philanthropist, and Founder of the Future Prowess Foundation School in Nigeria, Zannah Bukar Mustapha, has been named as the 2023 recipient of the Global Citizen Award at the 17th Global Citizenship Conference in Dubai, UAE.

LONDON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Internationally recognized humanitarian, philanthropist, and Founder of the Future Prowess Foundation School for orphans and less privileged children Zannah Bukar Mustapha has been named as the 2023 recipient of the Global Citizen Award, an annual tribute presented by leading international residence and citizenship advisory firm Henley & Partners, in partnership with the Swiss non-profit humanitarian organization Andan Foundation.

The prestigious award, which honors an individual who shows exceptional courage and commitment towards improving and supporting the global community, was presented at a gala reception during the 17th annual Global Citizenship Conference at the Shangri-La Hotel DIFC in Dubai, UAE, attended by heads of government, policymakers, leading academics, private client advisors, family offices, as well as many wealthy entrepreneurs and investors.

image00001

Mr. Mustapha played a critical role in mediating the release of over 100 of the Chibok school girls who were kidnapped by Islamic insurgency group Boko Haram in a remote part of Nigeria in April 2014, giving rise to the international #BringBackOurGirls campaign. The school he founded in 2007 in Maiduguri — the capital of Borno State and the epicenter of the Boko Haram rebellion — provides free education, meals, uniforms, and healthcare to children on both sides of the conflict as a sign of the reconciliation he hopes to achieve in the region.

Chairman of Henley & Partners and Founder of the Andan Foundation Dr. Christian H. Kaelin says Mr. Mustapha is a most worthy and inspiring recipient of the award. “As a champion for the safety and education rights of all displaced and orphaned children afflicted by the brutal violence in Northern Nigeria, Mr. Mustapha has demonstrated vision, exceptional courage, and innovation in driving change, and his actions and outlook are a valuable contribution towards a more just, peaceful, and tolerant world. He is a true ‘game changer,’ bridging gender, political, and religious divides by helping children on both sides of the conflict come together and learn under the same roof. We need more Zannah Mustaphas in the world.”

The Global Citizen Award selection process is based on a majority decision of the Global Citizen Award Committee. The award itself consists of a bespoke sculptural medal designed by leading Italian artist Antonio Nocera, an award certificate signed by the Chairman of the Global Citizen Award Committee, and a monetary prize of USD 25,000, which goes towards supporting the awardee’s humanitarian efforts. In addition, Henley & Partners commits to working closely with the awardee for a period of one year, raising awareness of their work and supporting the selected project through the firm’s network of more than 40 offices worldwide.

Since its inception, the Global Citizen Award has honored many remarkable individuals. The first laureate was German entrepreneur Harald Höppner, who set up the refugee humanitarian aid project Sea-Watch. Other previous recipients are Dr. Imtiaz Sooliman, Founder of the Gift of the Givers Foundation, Africa’s largest disaster relief organization, and Monique Morrow, Co-Founder of The Humanized Internet, a digital identity project that aims to bring hope to the estimated 1.1 billion individuals in the world who cannot prove their legal identity. Diep Vuong, Co-Founder and President of the Pacific Links Foundation, was awarded for her work in Southeast Asia, campaigning for the rights of those enslaved by human trafficking, and Prof. Dr. Padraig O’Malley received his Global Citizen Award in recognition of his work on conflict resolution and reconciliation in Iraq, Northern Ireland, and South Africa.

Thanking Henley & Partners and the Andan Foundation for their recognition of his work, Mr. Mustapha said, “Humanity’s interconnectedness in the global data sphere is now undeniable, constituting an expansive realm with limitless possibilities. In contrast, the unity among races, ethnicities, and citizens has grown increasingly delicate. Only global citizenship can heal.”

Media Contact:

Sarah Nicklin

Group Head of Public Relations

sarah.nicklin@henleyglobal.com

Mobile: +27 72 464 8965

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/73067ec7-8285-4333-849a-48dc9724ce41

GlobeNewswire Distribution ID 1000898595

OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

London, Nov. 09, 2023 (GLOBE NEWSWIRE) —
London, UK – November 9, 2023 – OPEN Health, a preeminent global provider of consultingHEOR and market accesspatient engagement, and scientific and creative communications services, will be presenting innovative research at the upcoming ISPOR Europe conference in Copenhagen, Denmark. OPEN Health experts will contribute to the event through workshops, panel discussions, and 24 posters. Key themes of OPEN Health’s research presented this year are patient preference, advanced modeling methodologies, and HTA policy changes. The majority of OPEN Health’s Scientific Office will be onsite to discuss the role of HEOR science in shaping policy, including Dr. Elisabeth Fenwick, Chief Scientific Officer; Professor Ben van Hout, Scientific Founder; Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes; Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access; and Maarten Treur, MSc, Vice President and Global Head of Modeling & Meta-Analysis.

Dr. Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, said: “I am extremely proud to see the research we do at OPEN Health being presented by our scientific experts at the ISPOR EU conference in Copenhagen. The range of research topics covered this year shows the extent of our expertise in advanced techniques as well as key therapeutic areas.”

Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes at OPEN Health, said: “The importance of patient preference information is that it brings a systematic approach to implement the idea of patient-focused drug development promoted by the FDA, the EMA, and various HTA bodies around the world. Indeed, the patient voice is key to patient adherence, and by helping to understand unmet needs, it is key to the success of a pharmaceutical product.”

Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access, said: “We are in a dynamic period of policy changes for access and HTA across regional, national, and international settings. HTA is taking a more prominent role in ensuring sustainable access to health innovations, while health innovations become exponentially more complex and expensive. We at OPEN Health are committed to understanding and shaping such changes through research and stakeholder engagement.”

OPEN Health will be presenting a virtual panel on November 10, ahead of ISPOR, on: EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025.” The panel is set to discuss several policy aspects regarding the current challenges and implications of the EU HTA regulation, covering topics such as the current position of EU HTA implementation, the major challenges expected across the industry, the stance of member states and various stakeholders, and strategies for the industry to prepare for joint clinical assessments. Register now to save your seat.

To learn more about our presence at ISPOR Europe, visit our website or meet the OPEN Health team at booth #C2-012 in Copenhagen.

 

About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient well-being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across consulting, HEOR and market access, scientific communications, patient engagement, and creative omnichannel communications. For more information on OPEN Health, visit www.openhealthgroup.com.

 

Press contact:

OPEN Health

Candice Subero, Vice President, Global Marketing

candicesubero@openhealthgroup.com

Attachment

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 8976596

OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

London, Nov. 09, 2023 (GLOBE NEWSWIRE) —
London, UK – November 9, 2023 – OPEN Health, a preeminent global provider of consultingHEOR and market accesspatient engagement, and scientific and creative communications services, will be presenting innovative research at the upcoming ISPOR Europe conference in Copenhagen, Denmark. OPEN Health experts will contribute to the event through workshops, panel discussions, and 24 posters. Key themes of OPEN Health’s research presented this year are patient preference, advanced modeling methodologies, and HTA policy changes. The majority of OPEN Health’s Scientific Office will be onsite to discuss the role of HEOR science in shaping policy, including Dr. Elisabeth Fenwick, Chief Scientific Officer; Professor Ben van Hout, Scientific Founder; Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes; Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access; and Maarten Treur, MSc, Vice President and Global Head of Modeling & Meta-Analysis.

Dr. Elisabeth Fenwick, Chief Scientific Officer at OPEN Health, said: “I am extremely proud to see the research we do at OPEN Health being presented by our scientific experts at the ISPOR EU conference in Copenhagen. The range of research topics covered this year shows the extent of our expertise in advanced techniques as well as key therapeutic areas.”

Dr. Marco Boeri, Director of Preference Research and scientific lead for Patient-Centered Outcomes at OPEN Health, said: “The importance of patient preference information is that it brings a systematic approach to implement the idea of patient-focused drug development promoted by the FDA, the EMA, and various HTA bodies around the world. Indeed, the patient voice is key to patient adherence, and by helping to understand unmet needs, it is key to the success of a pharmaceutical product.”

Emanuele Arcà, MSc, Senior Research Consultant in Strategic Market Access, said: “We are in a dynamic period of policy changes for access and HTA across regional, national, and international settings. HTA is taking a more prominent role in ensuring sustainable access to health innovations, while health innovations become exponentially more complex and expensive. We at OPEN Health are committed to understanding and shaping such changes through research and stakeholder engagement.”

OPEN Health will be presenting a virtual panel on November 10, ahead of ISPOR, on: EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025.” The panel is set to discuss several policy aspects regarding the current challenges and implications of the EU HTA regulation, covering topics such as the current position of EU HTA implementation, the major challenges expected across the industry, the stance of member states and various stakeholders, and strategies for the industry to prepare for joint clinical assessments. Register now to save your seat.

To learn more about our presence at ISPOR Europe, visit our website or meet the OPEN Health team at booth #C2-012 in Copenhagen.

 

About OPEN Health

OPEN Health unites deep scientific knowledge with wide-ranging specialist expertise to unlock possibilities that improve health outcomes and patient well-being. Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference. OPEN Health is a flexible global organization that solves complex healthcare challenges across consulting, HEOR and market access, scientific communications, patient engagement, and creative omnichannel communications. For more information on OPEN Health, visit www.openhealthgroup.com.

 

Press contact:

OPEN Health

Candice Subero, Vice President, Global Marketing

candicesubero@openhealthgroup.com

Attachment

Candice Subero
OPEN Health
candicesubero@openhealthgroup.com

GlobeNewswire Distribution ID 8976596

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) —  Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space.

“Since our founding we have believed that the next generation of biopharma leaders would operate at the intersection of scaled datasets and accelerated computing,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “Today, we are thrilled to share three major initiatives that support this belief and our mission to bring better medicines to patients at speed and scale. With Tempus’s 20 petabytes of fit-for-purpose precision oncology data, NVIDIA’s support in quadrupling our supercomputing power to rapidly and reliably advance the exploration and construction of large AI models, and updating our collaboration with Bayer to rapidly pursue a set of precision oncology programs, we will continue to drive the transformation from BioTech to TechBio together.”

Tempus Collaboration Provides Recursion with Access to Data Containing More Than 20 Petabytes of Proprietary Patient-Centric Oncology Data

Recursion has come to an agreement with Tempus for preferred access to one of the world’s largest proprietary, de-identified, patient-centric oncology datasets, spanning DNA, RNA, health records and more to support the discovery of potential biomarker-enriched therapeutics at scale through the training of causal AI models. By combining the forward genetics approach of Tempus with the reverse genetics approach at Recursion, the company believes it has an opportunity to improve the speed, precision and scale of therapeutic development in oncology. As part of the agreement, Recursion will pay Tempus up to $160M in cash or equity over the next five years in exchange for continued and updated data access and use rights for therapeutic development purposes.

“We share Recursion’s commitment to a data-first approach to precision medicine,” said Eric Lefkofsky, Founder and CEO of Tempus. “We look forward to working in tandem to leverage our multi-modal data to uncover insights that have the potential to advance personalized therapeutics for patients around the world.”

In aggregate, Recursion will now have access to approximately 50 petabytes of proprietary data across biology and chemistry as well as real-world, patient-centric data that is relatable and fit for the purpose of training large-scale AI/ML models, which it plans to use to drive novel therapeutic hypotheses, biomarker strategies, and patient cohort selection.

Top 50 Supercomputer Powered by NVIDIA

To accelerate the impact of the proprietary data Recursion has accumulated, the company has committed to substantially expanding BioHive-1, its on-premise NVIDIA DGX SuperPOD-based supercomputer, adding over 500 NVIDIA H100 Tensor Core GPUs to the more than 300 NVIDIA A100 Tensor Core GPUs already in place to increase its computational capacity 4X. This greatly expanded compute power will support the company’s pipeline, partnerships, and the construction of one of the largest foundation models of its kind across multiple modalities of biology and chemistry.

Based on the June 2023 TOP500 list, Recursion projects that upon completion and benchmarking, BioHive-1 will likely be in the top 50 most powerful supercomputers in the world across any industry and would be the most powerful supercomputer owned and operated by any biopharma company. The company anticipates the enhancement of BioHive-1 to be operational in the first half of 2024.

“A new era in drug discovery is here, and life science and drug discovery companies are leading the way,” said Jensen Huang, founder and CEO of NVIDIA. “Our ongoing collaboration with Recursion will bring scaled biological data together with one of the most powerful supercomputers to decode biology and get to better medicines faster.”

Collaboration with Bayer in Precision Oncology Programs

Recursion announced an updated collaboration with its established partner, Bayer, for a select set of precision oncology programs. This decision allows Bayer to leverage Recursion’s state-of-the-art capabilities to identify novel targets and chemistry applicable to oncology indications. Under the terms of the agreement, the companies may initiate up to seven oncology programs and Recursion is eligible to receive potential, success-based, future payments of up to $1.5 billion plus royalties on net sales.

“Our collaboration with Recursion is a testament to our commitment to shape the future of healthcare, using advancements in AI and drug discovery to push the boundaries of medicine with the aim of providing innovative cancer therapies for patients whose medical needs are not yet met by today’s treatment options,” said Stefan Oelrich, Member of the Board of Bayer AG and President, Pharmaceuticals.

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the outcomes and benefits expected from access to the real-world multimodal data held at Tempus; outcomes and benefits of deriving therapeutic hypotheses by linking molecular data and outcomes data; outcomes and benefits of expanding our supercomputer; early and late stage discovery, preclinical, and clinical programs, including timelines for data readouts; licenses and collaborations, including option exercises by partners and additional partnerships; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance, including cash runway; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “could,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q and our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

GlobeNewswire Distribution ID 8976094

Pacific Green Enters Agreement to Secure Strategic Site to Develop 0.5GW / 1.0GWh Battery Energy Park in South Australia

Dover, DE, Nov. 09, 2023 (GLOBE NEWSWIRE) — / Pacific Green Technologies, Inc. (“Pacific Green”), (OTCQB: PGTK) announces that Pacific Green Technologies (Australia) Pty Ltd., a wholly owned subsidiary of Pacific Green, has entered into an exclusivity agreement to secure a strategically located land site in Limestone Coast, South Australia to develop a 0.5 GW / 1.0 GWh battery energy park (the “Project”).

The Project will commence construction in 2024, with the energy park anticipated to be operational in 2026. When completed it will be the largest battery park in South Australia, connecting directly into an existing 275 kVA substation.

The Project will deliver a major increase in energy storage capacity in South Australia, reducing wholesale energy costs for the state, while also strengthening the region’s energy stability for communities and supporting South Australia’s net-zero transition.

Joel Alexander, Pacific Green’s Managing Director, Australia, commented: “We are excited to grow our portfolio into South Australia, which already has the highest adoption of renewable generation of all states in Australia. Our Limestone Coast Battery Energy Park can act as a load during the day, increasing the viability of even more solar and wind generation, whilst shifting energy to the times it is most valuable in the evening peak. This momentum allows us to accelerate progress towards South Australia achieving 100% net renewables by 2030.

Scott Poulter, Pacific Green’s CEO, added: “Coupled with our energy parks in Portland, Victoria, this agreement cements Pacific Green’s multi-gigawatt platform that will be deployed across Australia in the coming months and years.

About Pacific Green Technologies, Inc.:

Pacific Green is focused on addressing the world’s need for cleaner and more sustainable energy. It offers grid-scale battery energy storage systems, renewable and environmental technologies.

For more information, visit Pacific Green’s website:
www.pacificgreen.com

Notice Regarding Forward-Looking Statements:

This news release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the continued development of the Project, any potential business developments and future interest in Pacific Green’s battery, solar and environmental technologies.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the continuation of the development of the Project, general economic and political conditions. These forward-looking statements are made as of the date of this news release, and Pacific Green assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although Pacific Green believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all the information set forth herein and should also refer to the risk factors disclosure outlined in Pacific Green’s annual report on Form 10-K for the most recent fiscal year, Pacific Green’s quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Scott Poulter, Chairman & CEO
Pacific Green Technologies, Inc.
T: +1 (302) 601-4659

Joel Alexander, Managing Director
Pacific Green Technologies (Australia) Pty Ltd.
T: +61 497 335 833

GlobeNewswire Distribution ID 8976395

Nyxoah Reports Third Quarter 2023 Financial and Operating Results

Nyxoah Reports Third Quarter 2023 Financial and Operating Results
Partners with ResMed Germany to increase OSA awareness and therapy penetration

Mont-Saint-Guibert, Belgium – November 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the third quarter of 2023.

Recent Financial and Operating Highlights

  • Filed the third module in the modular PMA submission.
  • Accelerated U.S. pre-commercialization efforts, focused on market access around CPT coding.
  • Initiated a commercial partnership with strategic investor ResMed in Germany. This collaboration introduces a novel continuum of care into the German OSA market.
  • Reported third-quarter sales of €1.0 million and ended the quarter with 46 active German accounts.
  • Ended the quarter with a cash position of €72.5 million, providing an anticipated cash runway into late 2024.

“Nyxoah is entering one of the most exciting times in the company’s history. We will report data from our DREAM U.S. pivotal trial early next year, shortly thereafter complete our modular PMA submission, and expect FDA approval late 2024,” commented Olivier Taelman, Chief Executive Officer. “Hypoglossal nerve stimulation (HGNS) remains highly underpenetrated and guiding patients through their OSA journey is key to unlocking the market’s potential. Our agreement with ResMed Germany, which takes ResMed from a valued investor to commercial partner, creates a continuum of care that directs patients towards the appropriate treatment, resulting in greater therapy penetration.”

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)
 (in thousands)

For the three months ended September 30 For the nine months ended September 30
2023 2022 2023 2022
Revenue € 976 € 182 € 2,524 € 1,777
Cost of goods sold ( 336) ( 63) ( 930) ( 685)
Gross profit € 640 € 119 € 1,594 € 1,092
Research and Development Expense (6,568) (4,221) (19,330) (11,286)
Selling, General and Administrative Expense (5,058) (4,763) (16,794) (13,492)
Other income/(expense) 87 265 237
Operating loss for the period € (10,986) € (8,778) € (34,265) € (23,449)
Financial income 2,178 5,127 3,592 11,372
Financial expense (1,033) (2,524) (2 765) (5,473)
Loss for the period before taxes € (9,841) € (6,175) € (33,438) € (17,550)
Income taxes 2,229 (65) 1,119 ( 379)
Loss for the period € (7,612) € (6,240) € (32,319) € (17,929)
Loss attributable to equity holders € (7,612) € (6,240) € (32,319) € (17,929)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences ( 10) 100 ( 88) ( 14)
Total comprehensive loss for the year, net of tax € (7,622) € (6,140) € (32,407) € (17,943)
Loss attributable to equity holders € (7,622) € (6,140) € (32,407) € (17,943)
Basic Loss Per Share (in EUR) € (0.266) € (0.242) € (1.166) € (0.695)
Diluted Loss Per Share (in EUR) € (0.266) € (0.242) € (1.166) € (0.695)
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited)
(in thousands)
As at
September 30
2023
December 31 2022
ASSETS
Non-current assets
Property, plant and equipment 4,328 2,460
Intangible assets 45,720 39,972
Right of use assets 3,602 3,159
Deferred tax asset 47 47
Other long-term receivables 668 173
€ 54,365 € 45,811
Current assets
Inventory 1,709 882
Trade receivables 1,918 1,463
Other receivables 2,437 1,775
Other current assets 1,683 1,284
Financial assets 59,239 76,968
Cash and cash equivalents 13,250 17,888
€ 80,236 € 100,260
Total assets € 134,601 € 146,071
EQUITY AND LIABILITIES
Capital and reserves
Capital 4,926 4,440
Share premium 246,130 228,275
Share based payment reserve 7,468 5,645
Other comprehensive income 88 176
Retained loss (150,070) (118,212)
Total equity attributable to shareholders € 108,542 € 120,324
LIABILITIES
Non-current liabilities
Financial debt 8,407 8,189
Lease liability 2,990 2,586
Pension liability 75
Provisions 125 59
Deferred tax liability 6
€ 11,603 € 10,834
Current liabilities
Financial debt 769 388
Lease liability 788 719
Trade payables 4,480 4,985
Current tax liability 2,367 3,654
Other payables 6,052 5,167
€ 14,456 € 14,913
Total liabilities € 26,059 € 25,747
Total equity and liabilities € 134,601 € 146,071

Revenue

Revenue was €1.0 million for the third quarter ending September 30, 2023, compared to €182,000 for third quarter ending September 30, 2022.

Cost of Goods Sold

Cost of goods sold was €336,000 for the three months ending September 30, 2023, representing a gross profit of €640,000, or gross margin of 66.0%. This compares to total cost of goods sold of €63,000 in the third quarter ending September 30, 2022, for a gross profit of €119,000, or gross margin of 65.4%.

Research and Development Expenses

Research and development expenses were €6.6 million for the three months ending September 30, 2023, versus €4.2 million for the prior year period, driven by an acceleration in clinical activities, notably the start of the ACCCESS study.

Selling, General and Administrative Expenses

Selling, general and administrative expenses rose to €5.1 million for the third quarter of 2023, up from €4.8 million in the third quarter of 2022. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

Operating Loss

Total operating loss for the third quarter 2023 was €11.0 million versus €8.8 million in the third quarter of 2022. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities.

Cash Position
As of September 30, 2023, cash and financial assets totaled €72.5 million, compared to €94.9 million on December 31, 2022. Total cash burn was approximately €4.0 million per month during the third quarter of 2023.

Third Quarter 2023 Report
Nyxoah’s financial report for the third quarter 2023, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public today at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q3 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q3 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 22, 2023, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000898348

Cypriot judge C. Lycourgos reappointed at the EU Court of Justice

The Council of the EU has decided to reappoint Cypriot Constantinos Lycourgos as judge of the European Union Court of Justice in Luxembourg, according to an official statement. The representatives of the governments of the member states reappointed Constantinos Lycourgos and Jan Passer as judges of the Court of Justice, while Giovanni Pitruzzella was reappointed as advocate-general to the Court of Justice. The three appointments are for a term of office starting on 7 October 2024 and ending on 6 October 2030. They were carried out in the framework of the partial renewal of the composition of the Court of Justice in 2024. The Court of Justice of the EU consists of two courts: the Court of Justice and the General Court. The judges and advocates-general are appointed by common accord of the governments of the member states after consultation of a panel responsible for giving an opinion on prospective candidates' suitability to perform the duties concerned. Lycourgos was appointed as a judge at the Court of Justice of the EU on October 8th 2014, and has served as President of the Fourth Chamber since October 8th 2021.

Source: Cyprus News Agency